DBV Technologies SA – (DBVT) Stock Rating Reaffirmed by Leerink Swann

Leerink Swann reaffirmed their outperform rating on shares of DBV Technologies SA – (NASDAQ:DBVT) in a report published on Wednesday.

A number of other brokerages have also issued reports on DBVT. Societe Generale raised shares of DBV Technologies SA – from a hold rating to a buy rating in a research report on Thursday, March 16th. Jefferies Group LLC reaffirmed a buy rating and set a $47.00 target price on shares of DBV Technologies SA – in a research report on Thursday, March 16th. Zacks Investment Research lowered shares of DBV Technologies SA – from a buy rating to a hold rating in a research report on Tuesday, January 17th. Finally, Natixis raised shares of DBV Technologies SA – from a neutral rating to a buy rating in a research report on Friday, February 17th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $46.50.

Analyst Recommendations for DBV Technologies SA - (NASDAQ:DBVT)

Shares of DBV Technologies SA – (NASDAQ:DBVT) opened at 35.42 on Wednesday. The firm’s 50 day moving average is $35.33 and its 200-day moving average is $35.61. The company’s market capitalization is $1.63 billion. DBV Technologies SA – has a 52-week low of $27.02 and a 52-week high of $37.98.

Your IP Address:

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its stake in shares of DBV Technologies SA – by 115.8% in the second quarter. Royal Bank of Canada now owns 4,100 shares of the company’s stock valued at $133,000 after buying an additional 2,200 shares during the period. TD Asset Management Inc. acquired a new stake in shares of DBV Technologies SA – during the third quarter valued at about $272,000. Castleark Management LLC raised its stake in shares of DBV Technologies SA – by 136.9% in the fourth quarter. Castleark Management LLC now owns 9,690 shares of the company’s stock valued at $340,000 after buying an additional 5,600 shares during the period. Sectoral Asset Management Inc acquired a new stake in shares of DBV Technologies SA – during the third quarter valued at about $1,428,000. Finally, Norges Bank acquired a new stake in shares of DBV Technologies SA – during the fourth quarter valued at about $1,757,000. 48.96% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies SA – Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply